Volrustomig Priming Regimens Verkennende fase II-platformstudie (eVOLVE-01)
Een fase II, open-label onderzoek om de veiligheid, verdraagbaarheid, farmacokinetiek, immunogeniciteit en antitumoractiviteit van Volrustomig-primingregimes in combinatie met andere antikankermiddelen te evalueren bij deelnemers met solide tumoren (eVOLVE-01)
Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
This Phase II, platform, open-label, multicenter study will evaluate the efficacy, safety, and tolerability of volrustomig in combination with anticancer drugs in various solid tumor types.
This platform study currently includes 2 substudies:
Substudy 1: metastatic non-small cell lung cancer (mNSCLC) (non-squamous [NSQ]). Participants will be randomized in two treatment arms: Arm 1A and Arm 1B.
Substudy 2: mNSCLC (squamous [SQ] or NSQ). Participants will enroll to the Arm 2A only.
All arms will test a volrustomig dosing in combination with chemotherapy.
Studietype
Studietype
Inschrijving (Werkelijk)
Inschrijving
Fase
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
-
Beijing, China, 100730
- Research Site
-
Hangzhou, China, 310014
- Research Site
-
Jinan, China, 250013
- Research Site
-
Yantai, China, 264000
- Research Site
-
Zhengzhou, China, 450000
- Research Site
-
-
-
-
-
Bois-Guillaume, Frankrijk, 76031
- Research Site
-
Caen, Frankrijk, 14076
- Research Site
-
Dijon, Frankrijk, 21079
- Research Site
-
Montpellier, Frankrijk, 34070
- Research Site
-
-
-
-
-
Batumi, Georgië, 6010
- Research Site
-
Tbilisi, Georgië, 0144
- Research Site
-
Tbilisi, Georgië, 0112
- Research Site
-
Tbilisi, Georgië, '0159
- Research Site
-
Tbilisi, Georgië, 186
- Research Site
-
Tbilisi, Georgië, 0114
- Research Site
-
-
-
-
-
Athens, Griekenland, 115 27
- Research Site
-
Athens, Griekenland, 12462
- Research Site
-
Elaiones, Griekenland, 546 23
- Research Site
-
Piraeus, Griekenland, 185 47
- Research Site
-
Thessaloniki, Griekenland, 57001
- Research Site
-
-
-
-
-
Genoa, Italië, 16132
- Research Site
-
Meldola, Italië, 47014
- Research Site
-
Milan, Italië, 20133
- Research Site
-
Naples, Italië, 80131
- Research Site
-
Orbassano, Italië, 10043
- Research Site
-
Perugia, Italië, 06132
- Research Site
-
Rozzano, Italië, 20089
- Research Site
-
Udine, Italië, 33100
- Research Site
-
Verona, Italië, 37134
- Research Site
-
-
-
-
-
Kuala Lumpur, Maleisië, 59100
- Research Site
-
Kuching, Maleisië, 93586
- Research Site
-
Perai, Maleisië, 13700
- Research Site
-
-
-
-
-
Lisbon, Portugal, 1649-035
- Research Site
-
Lisbon, Portugal, 1169-050
- Research Site
-
Lisbon, Portugal, 1400-038
- Research Site
-
Porto, Portugal, 4099-001
- Research Site
-
-
-
-
-
Cluj-Napoca, Roemenië, 400641
- Research Site
-
Craiova, Roemenië, 200542
- Research Site
-
Floreşti, Roemenië, 407280
- Research Site
-
-
-
-
-
Belgrade, Servië, 11000
- Research Site
-
-
-
-
-
A Coruña, Spanje, 15009
- Research Site
-
Alcorcón, Spanje, 28922
- Research Site
-
Barcelona, Spanje, 08041
- Research Site
-
Madrid, Spanje, 28041
- Research Site
-
Málaga, Spanje, 29004
- Research Site
-
Pamplona, Spanje, 31008
- Research Site
-
Santander, Spanje, 39008
- Research Site
-
Santiago de Compostela, Spanje, 15706
- Research Site
-
Valencia, Spanje, 46026
- Research Site
-
Valencia, Spanje, 46015
- Research Site
-
-
-
-
-
Changhua, Taiwan, 50006
- Research Site
-
New Taipei City, Taiwan, 23561
- Research Site
-
Taipei, Taiwan, 106
- Research Site
-
Taipei, Taiwan, 110
- Research Site
-
-
-
-
California
-
Los Angeles, California, Verenigde Staten, 90067
- Research Site
-
-
North Carolina
-
Chapel Hill, North Carolina, Verenigde Staten, 27514
- Research Site
-
-
-
-
-
Seongnam, Zuid -Korea, 13620
- Research Site
-
Seoul, Zuid -Korea, 03722
- Research Site
-
Suwon, Zuid -Korea, 16247
- Research Site
-
-
-
-
-
Geneva, Zwitserland, 1205
- Research Site
-
Lausanne, Zwitserland, 1011
- Research Site
-
Winterthur, Zwitserland, 8401
- Research Site
-
Zurich, Zwitserland, 8091
- Research Site
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Key Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with no deterioration.
- Life expectancy greater than or equal to (>=) 12 weeks.
- Adequate organ and bone marrow function.
- Body weight greater than (>) 35 kilograms (kg) at screening and at randomization.
- Histologically or cytologically documented NSQ NSCLC in substudy 1 and SQ or NSQ mNSCLC in substudy 2.
- Absence of sensitizing epidermal growth factor receptor (EGFR) mutations.
- Absence of documented tumor genomic alteration results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted 1L therapies.
- At least one measurable lesion not previously irradiated that can be accurately measured at baseline as >= 10 millimeter (mm) in the longest diameter.
Key Exclusion Criteria:
- Spinal cord compression.
- History of primary active immunodeficiency.
- Active or prior documented autoimmune or inflammatory disorders.
- Mixed small-cell lung cancer and NSCLC histology or sarcomatoid variant.
- Brain metastases unless asymptomatic, stable, and not requiring steroids for at least 14 days prior to start of study intervention. A minimum of 2 weeks must have elapsed between the end of radiation therapy and study enrollment.
- Prior chemotherapy or any other systemic therapy for Stage IV NSCLC. Participants who have received prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for local disease are eligible, provided that progression has occurred greater (>) 12 months from end of last therapy.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: Substudy 1: Arm 1A: Volrustomig dose regimen 1 + Carboplatin and Pemetrexed
Volrustomig priming dose followed by volrustomig dosing regimen 1 in combination with carboplatin and pemetrexed. |
Participants will receive volrustomig via intravenous (IV) infusion.
Andere namen:
Participants will receive carboplatin via IV infusion. Participants will receive pemetrexed via IV infusion. |
|
Experimenteel: Substudy 1: Arm 1B: Volrustomig dose regimen 2 + Carboplatin and Pemetrexed
Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with carboplatin and pemetrexed. |
Participants will receive volrustomig via intravenous (IV) infusion.
Andere namen:
Participants will receive carboplatin via IV infusion. Participants will receive pemetrexed via IV infusion. |
|
Experimenteel: Substudy 2: Arm 2A: Volrustomig dose regimen 2 +Ramucirumab + Carboplatin + Pemetrexed or Paclitaxel
Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with ramucirumab and histology-specific chemotherapy (carboplatin+ either pemetrexed or paclitaxel). |
Participants will receive volrustomig via intravenous (IV) infusion.
Andere namen:
Participants will receive carboplatin via IV infusion. Participants will receive pemetrexed via IV infusion. Participants will receive ramucirumab via IV infusion. Participants will receive paclitaxel via IV infusion. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tijdsspanne: From screening (Days -28 to Day -1) up to 2 year 10 months
|
The safety and tolerability of volrustomig in combination with other anticancer drugs in participants with specified solid tumors will be assessed. |
From screening (Days -28 to Day -1) up to 2 year 10 months
|
|
Confirmed Objective Response rate (ORR)
Tijdsspanne: Up to 2 year 10 months
|
ORR is defined as the percentage of participants who have a confirmed complete response (CR) or confirmed partial response (PR), as per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1). |
Up to 2 year 10 months
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Disease Control Rate (DCR)
Tijdsspanne: Up to 2 year 10 months
|
DCR is defined as the percentage of participants who have a CR or PR or who have stable disease (SD) after the date of randomization or first dose. |
Up to 2 year 10 months
|
|
Duration of Response (DOR)
Tijdsspanne: Up to 2 year 10 months
|
DOR is defined as the time from the date of first documented response until the date of documented progression or death due to any cause (in the absence of progression). |
Up to 2 year 10 months
|
|
Progression Free Survival (PFS)
Tijdsspanne: Up to 2 year 10 months
|
PFS is defined as the time from randomization or first dose until radiological progression or death due to any cause (in the absence of progression). |
Up to 2 year 10 months
|
|
Overall Survival (OS)
Tijdsspanne: Up to 2 year 10 months
|
OS is defined as the time from randomization or first dose until the date of death due to any cause. |
Up to 2 year 10 months
|
|
Serum Concentration of Volrustomig
Tijdsspanne: Up to 2 year 10 months
|
The serum concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Trough concentration (Ctrough)
Tijdsspanne: Up to 2 year 10 months
|
The trough concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Maximum Observed Concentration (Cmax)
Tijdsspanne: Up to 2 year 10 months
|
The serum concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Area Under the Curve (AUC)
Tijdsspanne: Up to 2 year 10 months
|
The AUC concentrations of volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Number of Participants with Positive Antidrug Antibodies (ADAs)
Tijdsspanne: Up to 2 year 10 months
|
The incidence of ADAs against volrustomig or other anticancer agents in serum will be assessed. |
Up to 2 year 10 months
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Neoplasmata
- Ziekten van de luchtwegen
- Longziekten
- Neoplasmata van de luchtwegen
- Thoracale neoplasmata
- Longneoplasmata
- Carcinoom, bronchogeen
- Bronchiale neoplasmata
- Carcinoom, niet-kleincellige long
- Aminozuren, peptiden en eiwitten
- Eiwitten
- Organische chemicaliën
- Heterocyclische verbindingen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Koolwaterstoffen
- Cycloparaffins
- Koolwaterstoffen, alicyclisch
- Koolwaterstoffen, cyclisch
- Terpenen
- Antilichamen, monoklonaal, gehumaniseerd
- Antilichamen, monoklonaal
- Antilichamen
- Immunoglobulinen
- Immunoproteïnen
- Bloedeiwitten
- Serum -globulines
- Globulines
- Coördinatiecomplexen
- Guanine
- Hypoxanthines
- Purinones
- Purines
- Glutamaten
- Aminozuren, zuur
- Aminozuren
- Aminozuren, dicarbonylisch
- Taxoids
- Cyclodecanes
- Diterpenen
- Pemetrexed
- Ramucirumab
- Carboplatine
- Paclitaxel
Andere studie-ID-nummers
Andere studie-ID-nummers
- D798KC00001
- 2023-509482-20-00 (Register-ID: CTIS)
- 2023 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Qualified researchers can request access to anonymized individual patient-leveldata from AstraZeneca group of companies sponsored clinical trials via therequest portal Vivli.org. All requests will be evaluated as per the AZ disclosurecommitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes",indicates that AZ are accepting requests for IPD, but this does not mean allrequests will be approved.
IPD-tijdsbestek voor delen
AstraZeneca will meet or exceed data availability as per the commitment smade to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-toegangscriteria voor delen
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure researchenvironmentVivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .